Ovarian Cancer

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses treatment selection with PARP inhibitors in ovarian cancer.

As PARP inhibitors have now moved into the frontline maintenance setting in ovarian cancer, researchers are now seeking to even further capitalize on use of these agents, including indications in treatment-naïve patients.

Jeffrey M. Fowler, MD, discusses factors used to determine whether a patient with advanced ovarian cancer is eligible for primary cytoreductive surgery.

David O’Malley, MD, discusses the toxicities associated with PARP inhibitors in ovarian cancer.

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Updated guidelines from the United States Preventive Services Task Force on BRCA1/2 genetic testing recommend risk assessment, counseling, and genetic test-ing for women who meet certain criteria but fall short of encompassing important groups of individuals who are at risk for developing BRCA1/2 mutation–driven disease

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the University of Pittsburgh Medical Center faculty.

The FDA has approved niraparib (Zejula) for the treatment of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with ≥3 prior chemotherapy regimens, and whose cancer is associated with homologous recombination deficiency–positive status.

Antonio Gonzalez-Martin, MD, discusses the rationale for the phase III PRIMA trial investigating niraparib (Zejula) as maintenance therapy for patients with platinum-sensitive advanced ovarian cancer.

Robert L. Coleman, MD, FACOG, FACS, discusses what makes veliparib a unique agent in high-grade serous ovarian cancer.

The UK’s National Institute for Health and Care Excellence has approved rucaparib for the maintenance treatment of patients with relapsed ovarian, fallopian tube, or peritoneal cancer that has responded to platinum-based chemotherapy.

Jonathan A. Ledermann, MD, discusses the rationale for the randomized, double-blind, placebo-controlled, phase III ARIEL3 trial which explored rucaparib as maintenance therapy in women with high-grade, recurrent ovarian cancer who previously received platinum-based chemotherapy.

Laura L. Holman, MD, discusses screening options for ovarian cancer.

Updated results from the phase I/II MEDIOLA study strengthen the case for combining olaparib and durvalumab in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations. The updated data were featured in two separate presentations at the 2019 ESMO Congress.

Reagan M. Street, MD, MMS, discusses the shift toward targeted treatment in advanced ovarian cancer partly brought on by PARP inhibitors and the importance of hierarchical genomic testing.

Treatment with the MEK inhibitor trametinib significantly improves progression-free survival and leads to a strong trend toward improved overall survival in recurrent, low-grade serous ovarian cancer.

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.

Frontline maintenance therapy with the combination of olaparib and bevacizumab improved median progression-free survival versus bevacizumab and placebo for patients with newly diagnosed, advanced ovarian cancer.